Section Arrow
EWTX.NASDAQ
- Edgewise Therapeutics
Quotes are at least 15-min delayed:2026/09/06 06:07 EDT
Regular Hours
Last
 43.07
+1.12 (+2.67%)
Day High 
43.38 
Prev. Close
41.95 
1-M High
46.59 
Volume 
826.75K 
Bid
43.2
Ask
48.4
Day Low
41.6034 
Open
41.73 
1-M Low
40.64 
Market Cap 
4.56B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 43.24 
20-SMA 43.68 
50-SMA 42.21 
52-W High 48.4 
52-W Low 13.685 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.85/-1.67
Enterprise Value
4.56B
Balance Sheet
Book Value Per Share
4.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMRNImmuron Limited1.8+0.69+62.16%-- 
RXRXRecursion Pharmaceuticals3.63+0.19+5.52%-- 
CMNDClearmind Medicine Inc.1.16-0.54-31.76%-- 
MRNAModerna145.55-3.32-2.23%-- 
RAREUltragenyx Pharmaceutical15.3+0.45+3.03%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.